How should public health recommendations address Lp(a) measurement, a causative risk factor for cardiovascular disease (CVD)?-Reference-Cited by-同舟云学术

How should public health recommendations address Lp(a) measurement, a causative risk factor for cardiovascular disease (CVD)?

Published:2022-05 Issue: Volume:349 Page:136-143
ISSN:0021-9150
Container-title:Atherosclerosis
language:en
Short-container-title:Atherosclerosis

Author:

Catapano Alberico L.^ORCID,Daccord Magdalena,Damato Elaine,Humphries Steve E.,Neely R. Dermot G.,Nordestgaard Børge G.,Pistollato Michele,Steinhagen-Thiessen Elisabeth

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference43 articles.

1. Atherosclerosis;Libby;Nat. Rev. Dis. Prim.,2019

2. HEART UK consensus statement on Lipoprotein (a): a call to action;Cegla;Atherosclerosis,2019

3. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS);Mach;Eur. Heart J.,2020

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lipoprotein(a) in Children and Adolescents: Risk or Causal Factor for Cardiovascular Disease? A Narrative Review;International Journal of Molecular Sciences;2024-08-13

2. Genetics and Pathophysiological Mechanisms of Lipoprotein(a)‐Associated Cardiovascular Risk;Journal of the American Heart Association;2024-06-18

3. High lipoprotein(a): Actionable strategies for risk assessment and mitigation;American Journal of Preventive Cardiology;2024-06

4. Lipoproteína (a): ¿está indicada su determinación sistemática?;Endocrinología, Diabetes y Nutrición;2024-05

5. Lipoprotein (a): Is its systematic determination indicated?;Endocrinología, Diabetes y Nutrición (English ed.);2024-05